TABLE 2.
The cholesterol efflux activity (CE), cytotoxicity and haemolytic effects of human apoA‐I fragments and apoA‐I mimetic peptides (AAMPs)
| Peptide | CE (%; 10 μM), 12 h | Cell viability (%; 100 μM), 12 h | Haemolysis (%; 200 μM), 1 h |
|---|---|---|---|
| apoA‐I221–240 | 0.38 ± 0.24 | 84.27 ± 1.91 | 1.34 ± 0.66 |
| P1 | −1.17 ± 0.17 | 90.65 ± 4.93 | −1.84 ± 0.26 |
| P2 | 0.18 ± 0.13 | 89.40 ± 2.48 | 1.25 ± 0.65 |
| P3 | 0.91 ± 0.25 | 90.43 ± 3.40 | −0.28 ± 0.49 |
| P4 | 1.45 ± 0.15 | 84.20 ± 4.40 | 0.99 ± 0.66 |
| P5 | −0.12 ± 0.17 | 93.98 ± 2.71 | 1.20 ± 0.78 |
| P6 | 1.41 ± 0.11 | 97.80 ± 5.20 | −1.78 ± 0.17 |
| P7 | 2.29 ± 0.17 | 85.60 ± 3.20 | −0.74 ± 0.41 |
| P8 | 1.82 ± 0.13 | 87.50 ± 1.60 | −0.52 ± 0.49 |
| P9 | 3.09 ± 0.12 | 89.40 ± 2.20 | −0.37 ± 0.87 |
| P10 | 3.14 ± 0.22 | 106.70 ± 4.80 | −0.41 ± 0.60 |
| P11 | 3.30 ± 0.26 | 95.30 ± 3.90 | 1.64 ± 0.78 |
| P12 | 3.39 ± 0.28 | 106.77 ± 5.07 | 1.71 ± 0.73 |
| P13 | 4.33 ± 0.38 | 68.20 ± 5.30 | 1.99 ± 0.67 |
| P14 | 2.49 ± 0.44 | 66.00 ± 3.00 | 2.63 ± 0.70 |
| P15 | 4.01 ± 0.31 | 52.41 ± 3.16 | 7.06 ± 0.86 |
| P16 | 9.75 ± 0.97 | 42.61 ± 4.00 | 5.94 ± 0.58 |
| P17 | 12.23 ± 0.63 | 36.62 ± 3.40 | 7.86 ± 0.64 |
| L‐4F a | 3.61 ± 0.19 | 47.07 ± 1.89 | 2.10 ± 0.48 |
Note: Data are presented as the mean ± SEM. More detailed data are presented in the Supporting Information.
Abbreviations: apoA‐I, apolipoprotein A1.
a
L‐4F was used as a positive control.